Skip to content

Developing a brain health programme for people with Mild Cognitive Impairment to reduce dementia risk

Developing a holistic support programme for people with Mild Cognitive Impairment to reduce dementia risk and improve brain health

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN77616491
Enrollment
24
Registered
2026-06-17
Start date
2026-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A confirmed mild cognitive disorder conferring elevated risk of future dementia progression, including Mild Cognitive Impairment (MCI) and Subjective Cognitive Impairment (SCI) Mental and Behavioural Disorders

Interventions

The adapted intervention (HBA-UK) will be piloted with three groups, each comprising 8 patients. The intervention will be delivered in an accessible setting within Southmead Hospital, facilitated by t

Sponsors

North Bristol NHS Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. A confirmed mild cognitive disorder conferring elevated risk of future dementia progression. This includes (but is not limited to): Mild Cognitive Impairment (MCI) and Subjective Cognitive Impairment (SCI) 2. Previously seen in the Bristol Brain Centre, Southmead Hospital as a patient 3. Happy, comfortable and able to join a group with other patients 4. Willing and able to commit to travelling to the Bristol Brain Centre on a regular basis to attend a series of group sessions 5. Full capacity to provide informed consent to involvement 6. Between 50 - 90 years of age

Exclusion criteria

Exclusion criteria: 1. Montreal Cognitive Assessment (MoCA) <18/30 2. If someone has a psychiatric condition/diagnosis that would significantly impact on their ability to engage in a group, more appropriate to offer alternative support

Design outcomes

Primary

MeasureTime frame
Recruitment target measured using recruitment data at baseline assessment;Retention rate measured using participant enrolment data at post-intervention and follow-up assessments;Participant attendance measured using intervention attendance data at post-intervention assessment;Homework task adherence measured using homework data at post-intervention assessment;Session-by-session feedback measured using end-of-session questionnaires at throughout intervention delivery;Participant experience measured using programme questionnaire and feedback interview at post-intervention assessment;Acceptability of intervention measured using acceptability of intervention measure at post-intervention assessment;Intervention appropriateness measured using intervention appropriateness measure at post-intervention assessment

Secondary

MeasureTime frame
Verbal learning and memory measured using Rey Auditory Verbal Learning Test and Wechsler Memory Scale III Logical Memory at pre- and post-intervention and 3-month follow-up assessments;Non-verbal memory measured using Rey Osterrieth Complex Figure Test at pre- and post-intervention and 3-month follow-up assessments;Language generativity measured using verbal fluency tests (phonemic and semantic) at pre- and post-intervention and 3-month follow-up assessments;Psychomotor speed measured using Trail Making Test part A at pre- and post-intervention and 3-month follow-up assessments;Set-shifting/cognitive flexibility measured using Trail Making Test part B at pre- and post-intervention and 3-month follow-up assessments;Auditory-verbal working memory & attention measured using Wechsler Memory Scale III Digit Span at pre- and post-intervention and 3-month follow-up assessments;Subjective measure of memory failure measured using Everyday Memory Questionnaire – Revised at pre- and post-intervention and 3-month follow-up assessments;Knowledge, skills and confidence in managing own health measured using Partners in Health Scale and Healthy Brain Ageing Questionnaire at pre- and post-intervention and 3-month follow-up assessments;Mood and mental wellbeing measured using DASS-21 at pre- and post-intervention and 3-month follow-up assessments;Quality of Life measured using WHOQUOL-BREF at pre- and post-intervention and 3-month follow-up assessments;Sleep health measured using CogSleep Screener and Ru-SATED at pre- and post-intervention and 3-month follow-up assessments;Dementia risk index measured using CogDrisk at pre- and post-intervention and 3-month follow-up assessments

Countries

England, United Kingdom

Contacts

Public ContactDavid Woodstoke
david.woodstoke@bristol.ac.uk+44 117 455 9069

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 3, 2026